Doç. Dr. Seher Yıldız Tacar

Doctor and researcher Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi İstanbul
Breast NeoplasmsCarcinoma, Renal CellKidney NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 4 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Carcinoma, Renal Cell 2 publications
  • Kidney Neoplasms 2 publications
  • Carcinoma, Non-Small-Cell Lung 2 publications
  • Lung Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • InstitutionBakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 4 publications · Model version —From source
  • Publications32 publicationsOpenAlex, Europe PMCFrom source
  • ORCID0000-0001-7581-0962ORCIDFrom source
  • Last synchronised5 November 2026 08:55https://bakirkoysadikonukeah.saglik.gov.tr/TR-1498675/doktorlarimiz.html#seher-yildiz-tacarsaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

32 publications

  1. Consent architecture in biobanking: ethical attitudes and consent preferences among people with cancer and caregivers

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-17118-4 Open-access full textSource: OpenAlex

  2. Prognostic Value of BMI in Patients with Metastatic Cervical Cancer:A Retrospective Study From Turkey

    OncoTargets and therapy, 2026

    DOI 10.2147/ott.s622194 PMID 42644128 Open-access full textSource: Europe PMC

  3. Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma

    Tumori, 2026

    DOI 10.1177/03008916261490843 PMID 42847292 Source: Europe PMC

  4. Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy

    Medicina, 2025

    DOI 10.3390/medicina61071168 PMID 40731799 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  5. Understanding of Clinical Trials Among Patients With Cancer and Their Relatives

    JAMA Network Open, 2025

    DOI 10.1001/jamanetworkopen.2024.57020 PMID 39874033 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  6. The Relationship Between Changes in the Neutrophil-Lymphocyte Ratio (NLR) and Radiological Progression in Cervical Cancer

    Istanbul Medical Journal, 2025

    DOI 10.4274/imj.galenos.2025.59254 Open-access full textSource: OpenAlex

  7. The Relationship Between Hemoglobin to Albumin Ratio and Disease-Free Survival in Patients with Locally Advanced Nasopharyngeal Cancer Treated with Chemoradiotherapy

    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2025

    DOI 10.4274/bmj.galenos.2025.2025.3-8 Open-access full textSource: OpenAlex

  8. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

    Current Oncology, 2024

    DOI 10.3390/curroncol31090384 PMID 39330012 Open-access full textSource: OpenAlex

  9. Alectinib-induced Non-immune Hemolytic Anemia due to Erythrocyte Membrane Alterations: A Retrospective Evaluation

    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2024

    DOI 10.4274/bmj.galenos.2024.2024.3-9 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  10. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

    Journal of Geriatric Oncology, 2023

    DOI 10.1016/j.jgo.2023.101604 PMID 37683369 10 citations (Europe PMC) Open-access full textSource: OpenAlex

View all 32 publications